Promote Eliquis, a Direct Oral Anticoagulant with multiple indications in a highly competitve marketplace to Electrophysiology, Cardiology, Hematology Oncology, Pulmonology and Primary Care Physicians as well as those who play key roles in these practices. *Ranked in the top 5% in the nation through Q3 2018.*Peer award winner for outstanding leadership and contribution 2017.*Ranked in the top 20% in the nation 2017.*125% IC Target payout 2017.*Top growth among Hematology/Oncology specialists 2016. *Ranked in the top 15% in the nation 2015.*138% IC Target payout 2015.*3-Time Gold level award winner for achieving the highest market share for all 3 eligible quarters in 2015.*Increased market share from 11% to 40% in 2014.*Ranked in the top 15% in nation in 2014.*Fastest growing territory in the southeast region in 2014.*Ranked in the top 10% based on combined market share and growth.*149.6% average IC Target Payout in 2014.*#1 ranked territory in Tampa district in 2014.

Consistently achieved sales targets through educating physicians and staff on pharmaceutical products for various disease states. Launched several products successfully into the marketplace. Established strong relationships and credibility with physicians in the fields of Primary Care, Cardiology, Nephrology, Rheumatology, Neurology, Endocrinology, OB/GYN, and Gastroenterology.•Ranked 9th out of 108 overall in 2014 through the 1st quarter.•Top Outstanding Performer of the Year Award (Presidents Club) in 2013.•Finished 4th out of 101 in 2013 for overall performance.•Promoted to Executive Sales Consultant in 2013.•Finished in the top 5% with both cardiovascular products.•Ranked #1 in the region for overall volume with Reclast in 2012.•Top cardiovascular growth in the region in 2011.•Awarded MVP for outstanding leadership and performance in 2005 & 2007.•Multiple promotions (2005, 2008, 2013) for consistent sales success.•Finished 6th out of 111 in 2010 for overall performance.•Finished in the top 10% with Tekturna (2007) and Valturna (2010) launches.•Ranked in the top 10% nationally for overall performance in 2005.•Ranked in the top 5% nationally for lead product (Zelnorm) in 2005.

Consistently exceeded monthly quotas by effectively acquiring new commercial accounts, maintaining existing accounts, cold calling, networking, and setting appointments with key decision makers.•Awarded Top Salesperson 5 consecutive months (January-May) in 2004.•Exceeded monthly quota on average by 135% in 2004.•Ranked #1 out of 10 for newly acquired accounts and overall revenue.•100% of overall quota achieved in 2003.